Eloxx Pharmaceuticals, Inc. Overview
Pro stress-test →Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations. The company uplisted to the Nasdaq Capital Market with trading commencing on June 9, 2026, and has gained approximately 230% since its May 29, 2026 IPO.
Strategic Profile
Pro stress-test →The lead product candidate is ELX-02, a small-molecule drug designed to restore production of full-length functional proteins, currently in Phase 2 clinical development for treatment of Alport syndrome in patients with nonsense mutations. Eloxx has exclusively licensed ZKN-013 to Almirall, S.A., who is developing it for rare skin diseases.
Competitive Landscape
Pro stress-test →Eloxx operates in rare genetic disease therapeutics, competing indirectly with other rare disease specialists and larger biotech players developing treatments for cystic fibrosis, Alport syndrome, and other monogenic conditions. Direct competitors include other ribosome-modulating or nonsense suppression therapies in development, though limited approved therapies exist for the specific patient populations Eloxx targets.
Industry Context
Eloxx Pharmaceuticals, Inc. operates in Rare Disease Biopharmaceuticals.
Key facts
Founded: N/A · Headquarters: Arlington, Massachusetts, US · Employees: N/A · Revenue: N/A · Market cap: N/A